Efficacy of Darbepoetin alfa in Anemia Developed during Chemotherapy for Lung Cancer / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 104-109, 2009.
Article
in Korean
| WPRIM
| ID: wpr-52269
ABSTRACT
BACKGROUND:
Anemia is quite common in lung cancer patients and known to decrease the quality of life. Darbepoetin alfa is an erythropoiesis-stimulating protein approved for administration to cancer patients. This study examined the efficacy and safety of darbepoetin alfa in lung cancer patients with a hemoglobin concentration 10 g/dl. The efficacy and safety were measured by comparing the hemoglobin concentration and assessing the adverse events.RESULTS:
After chemotherapy, the hemoglobin concentration decreased to 9.03+/-0.64 g/dl. With the darbepoetin alfa treatment, the hemoglobin concentration increased to 10.09+/-1.17 g/dl after 4 weeks reaching a peak hemoglobin concentration of 10.45+/-1.18 g/dl. The changes in hemoglobin after 4 and 8 weeks with treatment were 1.08+/-1.24 g/dl and 1.38+/-1.59 g/dl (p<0.01). At least a 1 g/dl or more increase in hemoglobin was observed in 62.4% of patients. There were no serious adverse effects except for some mild reactions.CONCLUSION:
Darbepoetin alfa administered to lung cancer patients appears to be an effective, well-tolerated treatment for chemotherapy induced anemia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quality of Life
/
Hemoglobins
/
Erythropoietin
/
Darbepoetin alfa
/
Anemia
/
Lung
/
Lung Neoplasms
Limits:
Humans
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS